Novo Nordisk’s first foray into obesity comes through in Phase III

Damian Garde In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as ...

Takeda profits fall in first half as Actos sales contract

Eric Palmer Takeda COO Christophe Weber announced a revamped management structure in September that he is building in an effort to revive the Japanese drugmaker. And from the company's ...

Merck’s Gardasil successor could block 90% of cervical cancers–but first, uptake has to improve

Carly Helfand According to new research, Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide. But realizing ...

Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launch

Tracy Staton Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company ...

Amgen’s kidney dialysis drug clears its first Phase III hurdle

Damian Garde Amgen's in-development treatment for patients on kidney dialysis met its primary and secondary goals in a late-stage trial, step one in the drug's three-part Phase ...

Novartis-backed Sorbent grabs first tranche in $15M heart therapy round

John Carroll Sorbent Therapeutics has drawn down the first $ 6.5 million tranche of a $ 15 million venture round to finance a Phase IIb trial of its experimental heart therapy and ...

Who will be first of 2014 to be bought? Some say Jazz

Eric Palmer Industry analysts can't help but handicap which drugmakers will be the next target of heated industry M&A interest. So three days into the new year, they are putting ...

Roche’s Rituxan successor first up in market scramble for first-line treatment of CLL

Eric Palmer A number of drugmakers have been looking to get drugs across the finish line for approval of first-line use in the treatment of chronic lymphocytic leukemia, and Roche's ...

Zogenix shares soar after FDA approves first pure hydrocodone pain med

John Carroll The FDA has approved Zogenix's pain med Zohydro ER, sending its shares soaring on the reversal of fortunes for a drug that had been rejected by an expert panel late ...

First steps

joshua.slatko The newborn AbbVie came into being at the beginning of 2013, bringing with it the world’s best-selling prescription product and the rest of the legacy Abbott Labs biopharmaceuticals ...

Walmart, Lowe’s and Pacific Business Group on Health Announce a First of its Kind National Employers Centers of Excellence Network

barbara.lempert Innovative program to provide quality care for hip and knee replacement surgeries at no cost to employees SAN FRANCISCO, Oct. 8, 2013 /PRNewswire/ — Focusing ...

Heptares Delivers First Stabilised GPCR (Star) To Morphosys For Antibody Discovery

barbara.lempert Welwyn Garden City, UK and Boston, MA, USA, 10 October 2013 – Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS